Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

What Was Tested

This registered phase 3 trial tested Semaglutide.

It had four arms (groups): one (experimental), one (experimental), Semaglutide (active comparator) and Placebo (placebo comparator).

Participants will receive semaglutide once weekly.

The registry classes the interventions as drug.

Who Took Part

1270 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: BMI ≥35 kilograms per square meter (kg/m\^2). History of being unresponsive to at least 1 self-reported effort to lose weight with diet and/or exercise in the last 6 months.

The full record lists 2 inclusion and 10 exclusion criteria; among the exclusions: current diagnosis or history of diabetes mellitus; family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid cancer; uncontrolled hypertension or unstable cardiovascular disease.

How the Study Was Run

Design: randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Semaglutide.

Those kept unaware of assignments: participant and investigator.

It started in 2025-12-30 with completion listed for 2028-03.

It ran at 60 sites in United States (28), Bulgaria (9), Poland (8), United Kingdom (8) and Australia (7).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent Change From Baseline in Body Weight at Week 76 (time frame: Baseline, Week 76).

It also tracked 23 secondary outcomes, for example Change From Baseline in Waist Circumference, Change From Baseline in Absolute Body Weight, Change From Baseline in Systolic Blood Pressure (SBP), Percent Change From Baseline in Fasting Triglycerides, Percent Change From Baseline in Fasting High-density Lipoprotein (HDL)-cholesterol and Percent Change From Baseline in Fasting Non-HDL-cholesterol.

What This Means in Plain Language

Put simply, this is a phase 3, randomized trial of Semaglutide in 1270 people.

With 1270 participants it is a large trial for this field.

Its status is active not recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Semaglutide compound page, all human trials.